Neuroprotection market will reach $2.6 billion in 2014

Monday 21 May 2012, Amsterdam

A new report predicts that the overall world market for neuroprotective products will reach $2.6 billion for 2014. That revenue forecast appears in Neuroprotective Products: World Market Prospects 2012-2022, published in May 2012.

This new report forecasts that the neuroprotection products market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and drugs will gain regulatory approval. The scope of the field is widening, with many organisations entering and collaborating.

The pharmaceutical industry will develop more treatments for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising, the study reports. The main aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). Not all neuroprotective agents will be neuroregenerative, however.

Kritika Chaudhari, a pharmaceutical industry analyst, explains: “The emerging neuroprotection market in 2012 depends on the success of its R&D pipeline. The medical community regards neuroprotection as an important need in treating acute and chronic neurological conditions. Regulatory agencies also recognise the therapeutic potential of neuroprotective agents and have granted fast track designation and orphan drug status to product candidates. The strong R&D pipeline of neuroprotective agents offers marked sales potential after drug approvals.”

Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Another force driving the industry and market will be the treatment of brain injuries, especially those from traffic accidents.

This report provides revenue forecasts to 2022 at overall world market, therapeutic submarket and product level. It forecasts world sales for the following submarkets:

• Ion channel modulators
• Mitochondrial dysfunction regulators
• Anti-inflammatory and anti-apoptotic agents
• Neurotrophic factors
• Other neuroprotective treatments.

That investigation forecasts sales of leading agents, including Rasagiline, Minocycline, Memantine and NeuroSTAT. Research, data and analyses cover activities of Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and other pharmaceutical companies.

The analysis also contains research interviews with authorities in the industry.